Nkarta, Inc. (NKTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nkarta, Inc. (NKTX) closed at USD 2.03 on 2026-10-14, a change of -12.1 % over the past year, with a market capitalization of USD 138.24M.

Nkarta, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nkarta, Inc. key figures

Previous close

USD 2.03 (2026-10-14)

1-year change

-12.1 %

Market cap

USD 138.24M

Enterprise value

USD 29.01M

P/E ratio (trailing)

-1.33

P/E ratio (forward)

-1.10

EPS (trailing)

-1.45

EPS (forward)

-1.75

PEG ratio

n/a

Price to book

0.56

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.80

Employees

106

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nkarta, Inc. and compare it with other stocks.